ACR Highlights… ACR Convergence 2024 Highlights – Rare and Autoinflammatory diseases 19 Dec 202419 Dec 2024 Damage associated with disease-specific events and diagnostic or therapeutic procedures is highly prevalent in IgG4-related disease Abstract format and assignment number: Poster 0286 Presenting author: J. Stone (US) Date: Saturday,…
ACR Highlights… ACR Convergence 2024 Highlights – Paediatrics 19 Dec 202419 Dec 2024 Epstein-Barr Virus Infection Triggers Hyperinflammation and Cytokine Storm in Healthy Children Abstract format and assignment number: Oral presentation 0829 Presenting author: P. Lee (USA) Date: Saturday, 16th November 2024 This…
ACR Highlights… ACR Convergence 2024 Highlights – Health Professionals in Rheumatology (HPR) 19 Dec 202419 Dec 2024 Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup Abstract format and assignment number: Oral presentation 0794 Presenting author: S. K. Gandhi (USA) Date:…
Connective Tissue Diseases and Vasculitis… EULAR 2024 Highlights – Vasculitis and other Connective Tissue Diseases 21 Jul 202422 Jul 2024 Author: Jan Schirmer Blockmans et al. (LBA0001) reported the results of the SELECT-GCA trial that compared Upadacitinib (either 15 or 7.5 mg daily combined with a 26 week prednisone taper)…
EULAR 2024 Highlights… EULAR 2024 Highlights – RA I – Clinical (non-therapeutic) 21 Jul 202421 Jul 2024 Author: Dálifer Freites Núñez Gerritsen et al. (POS0652) created a prediction model based on volatile organic compounds (VOCs) in exhaled breath to differentiate between patients with rheumatoid arthritis (RA) and…
EULAR 2024 Highlights… EULAR 2024 Highlights – RA II – Clinical (therapeutic) 21 Jul 202421 Jul 2024 Author: Daliya Pencheva Aymon et al. (OP0092) assessed the incidence of infections in rheumatoid arthritis (RA) patients from 14 RA registries in the JAK-POT study. Data from 54,905 treatment initiations,…
EULAR 2024 Highlights… EULAR 2024 Highlights – Spondyloarthritis I – non-therapeutic 21 Jul 202421 Jul 2024 Author: Bayram Farisogullari Da Silva et al. (POS0005) compared the spinal symptoms at baseline and after two years in early axial spondyloathritis (axSpA) patients (n = 267) and non-axSpA chronic…
EULAR 2024 Highlights… EULAR 2024 Highlights – Spondyloarthritis II – therapeutic 21 Jul 202421 Jul 2024 Author: Jean-Guillaume Letarouilly Webers et al. (OP0060) investigated which ASDAS cut-off values correspond best with treatment intensification (TI) in practice through the prospective multicentre Dutch registry for patients with SpA…
Basic and Translational Research… EULAR 2024 Highlights- Basic and Translational Research 21 Jul 202422 Jul 2024 Author: Giacomo Cafaro Toitou et al. (OP0056) investigated the biology of CD74+ synovial fibroblasts (SF) in rheumatoid arthritis (RA) and found that RA T-cells are able to induce the expression…
EULAR 2024 Highlights… EULAR 2024 Highlights – People with Arthritis / Rheumatism across Europe (PARE) 21 Jul 2024 Author: Sladjana Rumpl Tunjic Beesley et al. (OP0102) presented the development and implementation of novel and innovative approaches for raising awareness of childhood arthritis. Raising awareness that children and young people get arthritis is…